Rehmannioside D prevents estrogen-deficiency induced osteoporosis by interacting with c-Jun to dismantle the AP-1 complex and suppress MAPK/NF-κB signaling
{{output}}
Background: Postmenopausal osteoporosis (PMOP) necessitates novel therapeutics with defined targets. Rehmannioside D (RD), a bioactive compound from Rehmannia glutinosa, exhibits anti-inflammatory properties, yet its anti-osteopo... ...
